Managing risk across complex pharma supply chains

Distributor monitoring is annual at most companies - a static review of filed accounts already 12 months out of date. When a distributor starts delaying payments, the signal gets missed until receivables cross a threshold that makes intervention difficult. By then, the distributor is often quietly liquidating inventory to manage its own cash position.

Distributor Performance Management monitors financial signals continuously - trade credit behaviour, payment patterns, court filings, and external news - and surfaces early-warning alerts ranked by exposure value. Teams see a live risk score per distributor, not a once-a-year snapshot.

Credit managers get 60–90 days of advance notice on deteriorating accounts - enough time to adjust credit terms, require bank guarantees, or redirect inventory before the situation becomes a write-off.

After years of geographic expansion, a pharma company's distributor network had grown to over 180 partners across 14 markets. Each market team managed its own relationships using different tools and risk criteria. There was no consolidated view of concentration risk - which distributors held the largest combined credit lines, and which markets were overexposed to a single partner.

The platform creates a single, comparable risk view across the entire distributor base regardless of market - standardising signals so a deteriorating distributor in Vietnam surfaces with the same clarity as one in Germany. Portfolio-level concentration reports show where credit exposure is clustering.

The credit committee gets a consolidated portfolio view for the first time. Within the first review cycle, three markets were flagged for over-concentration - two of which had no awareness of the issue at country level.

Entering a new market - Southeast Asia, Sub-Saharan Africa, Eastern Europe - often means partnering with distributors who have limited formal financial records, no credit bureau presence, and relationships built on reputation. Sales teams push to move fast. Finance teams have almost nothing to underwrite the credit decision against.

Privue aggregates alternative data signals - trade references, payment network behaviour, ownership structures, legal filings, and local news - to build a risk profile even where formal financials are thin or absent. Initial credit terms can be sized against actual evidence rather than gut feel.

New market entries proceed with a structured credit rationale rather than a binary approve/reject based on incomplete information. Initial terms are calibrated to the risk, with automatic review triggers as the relationship develops.

A pharma company's largest domestic customer - a hospital group representing 18% of local revenue - was acquired by a private equity firm. The finance team assumed continuity. What followed was six months of delayed payments, disputed invoices, and a request to renegotiate terms. The acquisition had been public knowledge for months; the risk implications never reached the order-to-cash team.

Large Customer Risk Assessment monitors hospital groups and pharmacy chains continuously - tracking ownership changes, financial stress indicators, and credit events. Exposure is shown in monetary terms against outstanding receivables, so the finance team always sees risk as a cash number, not an abstract score.

The acquisition triggers an alert at announcement, giving the team months to renegotiate payment terms proactively rather than reacting to missed invoices after the fact.

Across several Southern European markets, public hospital systems facing budget pressure had begun extending payment cycles - from 90 days to 180, sometimes beyond. Individual country teams knew their local situation but there was no aggregated view of how much this sector-wide stress was accumulating on the balance sheet. The CFO had no reliable answer to what the true net exposure to public healthcare customers actually was.

The platform monitors sector-level financial stress signals alongside individual customer data - enabling a portfolio view of public healthcare exposure by market, with payment cycle trends and concentration flags. Country-level data rolls up into a regional picture the CFO can act on.

Finance leadership gets a quarterly receivables risk report segmented by customer type and market - a first. Two markets previously considered low-risk were reclassified, and provisions adjusted accordingly before year-end audit.

A pharma company had outsourced a Phase II trial to a mid-tier CRO. Due diligence at contract signing was thorough. Eighteen months later, the CRO's parent company ran into difficulties in a separate business unit. Rumours were circulating. The trial team had no formal mechanism to track this and learned about it from a trade publication - at which point contingency planning felt alarmingly late.

Vendor Due Diligence treats onboarding as the start of monitoring, not the end of it. Financial health, regulatory history, litigation activity, and key personnel changes are tracked continuously throughout the relationship - so due diligence is a programme, not a one-time gate.

The parent company's difficulties surface as an alert within days of becoming public, giving the trial team time to assess options and engage the CRO directly - rather than managing a crisis mid-trial.

A strategic review revealed that a single contract manufacturer had quietly become responsible for the majority of production for one of the company's top-five products - through a combination of acquisitions and contract renewals handled by different procurement teams over several years. No single person had visibility of the full picture. The concentration had never been deliberately chosen; it had accumulated.

Vendor Due Diligence maps ownership structures and entity relationships across the vendor base, surfacing hidden concentration - where multiple vendors are ultimately controlled by the same parent, or where one partner has grown to represent disproportionate supply risk.

Procurement leadership gets a clear concentration map across the manufacturing base. Diversification decisions become deliberate rather than reactive - addressed during contract renewals, not after a supply disruption.

A European pharma group faced its first CSRD reporting cycle with 400+ active suppliers across 30 countries. Questionnaire responses had come back from fewer than 20% of them - the rest were blank. Manually chasing the data would take months and still leave gaps. Investors were asking questions the company couldn't answer with confidence, and the compliance deadline was fixed.

Sustainability Assessment covers the gaps - generating ESG scores, climate risk flags, and emissions estimates for every supplier using third-party data, even where the supplier hasn't self-reported. Findings are mapped automatically against CSRD, FDA, and investor framework requirements, with a full audit trail.

The ESG team went from 20% coverage to near-complete visibility across the supply base in weeks. The compliance report that previously required a full quarter to compile was ready in under three weeks.